CHOP researchers identify key target responsible for treatment failure in patients with hemophilia A
Researchers at Children's Hospital of Philadelphia (CHOP) have identified a key target that may be responsible for treatment failure in […]
The combination of ibrutinib plus rituximab is approved for the treatment of adults with previously untreated chronic lymphocytic leukemia (CLL). […]rituximab
Ibrutinib with rituximab in previously untreated CLL: Indication of added benefit over FCR